Accuracy of PET-CT in predicting survival in patients with esophageal cancer

World Journal of Surgery

Volumn 36, Issue 5, 2012, Pages 1089-1095

  Brown, Claire ^a   Howes, Ben ^a   Jamieson, Glyn G ^a   Bartholomeusz, Dylan ^b   Zingg, Urs ^a   Sullivan, Thomas R ^a   Thompson, Sarah K ^a,b  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; ESOPHAGUS RESECTION; ESOPHAGUS TUMOR; EVALUATION; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 84863724171     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-012-1470-y     Document Type: Article

References (43)

1. National Comprehensive Cancer network, Inc (2010) NCCN practice guidelines in oncology. Esophageal cancer. Version 1.2010. Available at http://www.nccn.org/professionals/physician-gls/f-guidelines.asp [accessed November 8, 2010]
2. Skehan SJ, Brown AL, Thompson M et al (2003) Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics 20:713-723
3. Pan LL, Gu P, Huang G et al (2009) Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 21:1008-1015
4. 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. Ann Thorac Surg 81:1076-1081
5. 18FDG uptake in esophageal adenocarcinoma: linking biology and outcome. J Cancer Res Clin Oncol 134:227-236
6. Omloo JM, Sloof GW, Boellaard R et al (2008) Importance of fluorodeoxyglucose-positron emission tomography (FDG-PET) and endoscopic ultrasonography parameters in predicting survival following surgery for esophageal cancer. Endoscopy 40:464-471
7. max in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. J Thorac Oncol 4:875-879
8. Shenfine J, Barbour AP, Wong P et al (2009) Prognostic value of maximum standardized uptake values from preoperative positron emission tomography in resectable adenocarcinoma of the esophagus treated by surgery alone. Dis Esophagus 22:668-675
9. Aly A, Jamieson GG, Pyragius M et al (2004) Antireflux anastomosis following esophagectomy. ANZ J Surg 74:434-438
10. Zhang X, Watson DI, Jamieson GG et al (2005) Outcome of esophagectomy for adenocarcinoma of the esophagus and oesophagogastric junction. ANZ J Surg 75:513-519
11. Medical Services Advisory Committee (2008) Positron emission tomography for oesophageal and gastric cancer. Assessment report. Available at http://www.msac.gov.au/internet/msac/publishing.nsf/Content/ 8FD1D98FE64C8A2FCA2575AD0082FD8F/$File/MSAC-35b-i-PET-gastroesophageal- toprint-FINAL%20to%20print-301008.pdf [accessed November 12, 2010]
12. Wong R, Walker-Dilks C, Raifu AO (2009) Recommendation report - PET #4. PET imaging in esophageal cancer. Available at: http://www.cancercare.on.ca/ common/pages/UserFile.aspx?fileId=43135 [accessed December 12, 2010]
13. Palser T, Cromwell D, van der Meulen et al. (2008) National oesophago-gastric cancer audit: an audit of the care received by people with oesophago-gastric cancer in England and Wales. First Annual Report 2008. Available at http://www.ic.nhs.uk/webfiles/Services/NCASP/Cancer/ New%20web%20documents%20(OG)/28010208-NHSIC-OGAuditReport-FV-HR.pdf [accessed December 12, 2010]
14. Facey K, Bradbury I, Laking G et al. (2007) Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess 11:iii-iv, xi-267
15. Vliet EPM, Heijenbrok-Kal MH, Hunink MGM et al (2008) Staging investigations for esophageal cancer: a meta-analysis. Br J Cancer 98:547-557
16. Cerfolio RJ, Bryant AS (2006) Maximum standardized uptake values on positron emission tomography of esophageal cancer predicts stage, tumor biology, and survival. Ann Thorac Surg 82: 391-395
17. Cheze-Le Rest C, Metges JP, Teyton P et al (2008) Prognostic value of initial fluorodeoxyglucose-PET in esophageal cancer: a prospective study. Nucl Med Commun 29:628-635
18. 18F- fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery 144:793-802
19. Sepesi B, Raymond DP, Polomsky M et al (2009) Does the value of PET-CT extend beyond pretreatment staging? An analysis of survival in surgical patients with esophageal cancer. J Gastrointest Surg 13:2121-2127
20. Fukunaga T, Okazumi S, Koide Y et al (1998) Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. J Nucl Med 39:1002-1006
21. Kato H, Kuwano H, Nakajima M (2002) Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94:921-928
22. 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications. J Nucl Med 45:1843-1850
23. Westreenen HL, Plukker JTM, Cobben DCP (2005) Prognostic value of the standardized uptake value in esophageal cancer. AJR Am J Roentgenol Radium Ther Nucl Med 185:436-440
24. Choi JY, Jang KT, Shim YM (2006) Prognostic significance of vascular endothelial growth factor expression and microvessel density in esophageal squamous cell carcinoma: comparison with positron emission tomography. Ann Surg Oncol 13:1054-1062
25. 18F-FDG in esophageal cancer. World J Surg 32:69-75
26. 18F-fluorodeoxygloucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer 115:3196-3203
27. 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 21:428-432
28. Hong D, Lunagomez S, Kim EE et al (2005) Value of baseline positron emission tomography for predicting overall survival in patients with nonmetastatic esophageal or gastroesophageal junction carcinoma. Cancer 104:1620-1626
29. Stahl A, Stollfuss J, Ott K et al (2005) FDG PET and CT in locally advanced adenocarcinomas of the distal oesophagus. Clinical relevance of a discordant PET finding. Nuklearmedizin 44:249-255
30. Ott K, Weber WA, Lordick F (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24:4692-4698
31. Konski AA, Cheng JD, Goldberg M et al (2007) Correlation of molecular response as measured by 18-FDG PET with outcome after chemo-radiation in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys 69:358-363
32. Weider HA, Ott K, Lordick F et al (2007) Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. Eur J Nucl Med Mol Imaging 34:1925-1932
33. Chatterton BE, Shon IH, Baldey A (2009) Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study. Eur J Nucl Med Mol Imaging 36:354-361
34. 18F-fluoro-2-deoxy-D-glucose positron emission tomography results on survival and pathologic response in patients with gastroesophageal cancer undergoing chemoradiation. Cancer 115: 624-630
35. Kato H, Kuwano H, Nakajima M et al (2002) Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184:279-283
36. West CML, Charnley N (2005) The potential of PET to increase understanding of the biological basis of tumor and normal tissue response to radiotherapy. Br J Radiol Suppl 28:50-54
37. Vaupal P, Mayer A (2007) Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 26:225-239
38. Soret M, Bacharach SL, Buvat I (2007) Partial-volume effect in PET tumor imaging. J Nucl Med 48:932-945
39. Adams MC, Turkington TG, Wilson JM et al (2010) A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 195:310-320
40. Scheuermann JS, Saffer JR, Karp JS (2009) Qualification of PET scanners for use in multicenter cancer clinical trials: the American College of Radiology Imaging Network experience. J Nucl Med 50:1187-1193
41. Thompson SK, Ruszkiewicz AR, Jamieson GG et al (2008) Improving the accuracy of TNM staging in esophageal cancer: a pathological review of resected specimens. Ann Surg Oncol 15:3447-3458
42. Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York
43. Bruzzi JF, Munden RF, Truong MT et al (2007) PET/CT of esophageal cancer: its role in clinical management. Radiographics 27:1635-1652